Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 56 of 146 for:    acne AND erythema

Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03767400
Recruitment Status : Recruiting
First Posted : December 6, 2018
Last Update Posted : April 19, 2019
Sponsor:
Information provided by (Responsible Party):
Allergan

Tracking Information
First Submitted Date December 5, 2018
First Posted Date December 6, 2018
Last Update Posted Date April 19, 2019
Actual Study Start Date December 7, 2018
Estimated Primary Completion Date May 31, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: December 5, 2018)
  • VivoSight software measurements of Epidermal Thickness [ Time Frame: Day 1 ]
    Epidermal thickness will be measured in microns.
  • VivoSight software measurements of surface roughness [ Time Frame: Day 1 ]
    Surface roughness measurements (Ra, Rq, Rz) will be measured in microns.
  • VivoSight software measurements of redness [ Time Frame: Day 1 ]
    Redness will be measured in number of pixels.
  • VivoSight software measurements of attenuation coefficient [ Time Frame: Day 1 ]
    Attenuation coefficient will be measured per cm (cm-1).
Original Primary Outcome Measures Same as current
Change History Complete list of historical versions of study NCT03767400 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: December 5, 2018)
  • Overall Photodamage Score at Day 1 [ Time Frame: Day 1 ]
    The Investigator will assess the participant's overall photodamage using a 10-point scale where (0) = None to (9) = Severe).
  • Overall Appearance of Fine Lines/Wrinkles Cheek Areas [ Time Frame: Day 1 ]
    The investigator will assess the participant's appearance of fine lines/wrinkles using a 5-point scale from (0=None to 4=Diffuse).
  • Post-study Dynamic Optical Coherence Tomography (D-OCT) Image Analysis of Epidermal Thickness [ Time Frame: Day 1 ]
    Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert.
  • Post-study D-OCT Image Analysis of Density and Attenuation Coefficient of Epidermis [ Time Frame: Day 1 ]
    Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert.
  • Post-study D-OCT Image Analysis of Density and Attenuation Coefficient of Superficial Dermis [ Time Frame: Day 1 ]
    Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert.
  • Post-study D-OCT Image Analysis of Collagen Fibers [ Time Frame: Day 1 ]
    Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert. Measured as normal or in bundles.
  • Post-study D-OCT Image Analysis of Integrity of Collagen [ Time Frame: Day 1 ]
    Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert. Measure as (few, moderate, or many fragments).
  • Post-study D-OCT Image Analysis of Score of Vessels [ Time Frame: Day 1 ]
    Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert. Measured at 300 and 500 microns.
  • Post-study D-OCT Image Analysis of Vascularity Quantification with Thresholds [ Time Frame: Day 1 ]
    Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert. Measured at 300 and 500 microns depth.
  • Blinded Independent Physician Assessor Grading of the D-OCT Images of Stratum Corneum Reflectivity [ Time Frame: Day 1 ]
    Grading (0 = absent to 3 = high).
  • Blinded Independent Physician Assessor Grading of the D-OCT images of Upper Dermal Reflectivity [ Time Frame: Day 1 ]
    Grading (0 = absent to 3 = high).
  • Blinded Independent Physician Assessor Grading of the D-OCT Images of Dermoepidermal Contrast [ Time Frame: Day 1 ]
    Grading (0 = absent to 3 = high).
  • Blinded Independent Physician Assessor Grading of the D-OCT images of Vessel Density [ Time Frame: Day 1 ]
    Grading (0 = no vessels to 3 = many vessels).
  • Antera 3D Images [ Time Frame: Day 1 ]
    The investigator will capture 3D images utilizing the Antera 3D.
  • VISIA-CR Images [ Time Frame: Day 1 ]
    The investigator will capture standardized digital photographs utilizing the VISIA-CR.
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.
Official Title Dynamic Optical Coherence Tomography (D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.
Brief Summary This single-center clinical study is being conducted over the course of 2 weeks to conduct an exploratory pilot study as a preliminary evaluation of D-OCT's ability to measure skin changes from aging. Assess structural differences between young and aged skin on the face. To identify the structural characteristics of atrophic acne scars relative to normal skin on the face. To explore characteristics of cellulite relative to normal skin on the thigh in young and aged skin.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Female Caucasian subjects with Fitzpatrick skin types I-III that meet one of the criteria listed; ages 18-30 years old without acne scars on the face with or without visible cellulite on posterior thigh, or ages 55-75 years old without acne scars on the face with or without visible cellulite on posterior thigh, or ages 18-75 years old with atrophic acne scars.
Condition Skin Care
Intervention
  • Device: Skin Imaging
    Non-invasive in vivo skin imaging will be taken with the VivoSight D-OCT and the measurements will be acquired post-study utilizing VivoSight software.
  • Other: Facial Cleanser
    Participants will be instructed to remove all makeup from the face and cleanse the face with SkinMedica Facial Cleanser at least 15 minutes prior to investigator assessments and photography, and at least 30 minutes prior to use of D-OCT. Particiapnts in the cellulite group will have the thigh area cleansed with Facial Cleanser at least 15 minutes prior to photography and at least 30 minutes prior to use of D-OCT. For standardization, this procedure will be performed with SkinMedica Facial Cleanser (to remove makeup and cleanse the face and thigh (if applicable)) for all the participants.
    Other Name: SkinMedica® Facial Cleanser
Study Groups/Cohorts
  • Group A - Young skin (18 - 30 years old)
    Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
    Interventions:
    • Device: Skin Imaging
    • Other: Facial Cleanser
  • Group B - Aged skin (55 - 75 years old)
    Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
    Interventions:
    • Device: Skin Imaging
    • Other: Facial Cleanser
  • Group C - Atrophic acne scars (18 - 75 years old)
    Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
    Interventions:
    • Device: Skin Imaging
    • Other: Facial Cleanser
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: December 5, 2018)
110
Original Estimated Enrollment Same as current
Estimated Study Completion Date May 31, 2019
Estimated Primary Completion Date May 31, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Female Caucasian subjects with Fitzpatrick skin types I-III that meet one of the criteria listed below:

    1. Ages 18-30 years old without acne scars on the face with or without visible cellulite on posterior thigh, or
    2. Ages 55-75 years old without acne scars on the face with or without visible cellulite on posterior thigh, or
    3. Ages 18-75 years old with atrophic acne scars
  • Subject has completed an appropriately administered informed consent process which includes signing the IRB approved consent form.
  • Good general health and free of any disease state or physical condition (e.g. psoriasis, rosacea, scars, tattoos etc.) which, in the investigator's opinion, might impair evaluations of the test sites or expose the subject to an unacceptable risk by study participation.
  • Willingness to remove all makeup on the day of the visit. Makeup may be applied after the study visit has been completed.
  • Willingness to cleanse their face and remove all face makeup at each scheduled clinic visit. No other topical products should be applied to the face until the study visit has been completed.

    i. For cellulite subgroup, willingness to have thigh cleansed at each scheduled clinic visit.

  • Willingness to have investigator exams, skin instrumentation measurements, and digital photos performed on the face and/or thigh (for cellulite subgroup).
  • Women of childbearing potential must not be pregnant at the time of the study.

Exclusion Criteria:

  • Has any condition that, in the opinion of the investigator, would make it unsafe for the subject to participate in the study or interfere with their clinical assessments (including conditions that require the concurrent use of anticoagulants, bleeding coagulopathies, photosensitivity diseases).
  • Individuals with active symptoms of allergy, cold sore or warts, active psoriasis or eczema, rosacea, sunburn, open wounds, neurotic excoriations, tattoos, or other skin conditions in the test areas that would interfere with the assessments of this study.
  • Individuals who are pregnant.
  • Uncontrolled disease such as diabetes, hypertension, hyper or hypo-thyroidism, active hepatitis, immune deficiency, or autoimmune.
  • Individuals who have a pre-existing or dormant dermatologic condition (e.g. history of severe psoriasis, atopic dermatitis, rosacea, skin cancer, etc.)
  • Individuals who have routinely used any of the following topical products, prescription products, or had any of the listed treatments/procedures within the listed time frame prior to study entry or will use during study:

    1. Any product that the investigator deems that could affect the study objectives. These include products that address skin imperfections. This does not include a basic cleanser, moisturizer and sunscreen.(time frame 2 weeks)
    2. Chemical peel, microdermabrasion, dermaplaning, or microneedling (time frame 3 months)
    3. Retin-A®, Retin-A Micro®, Renova®, Avita®, Tazorac®, Avage® or Differin® or other similar prescription drugs (time frame 3 months)
    4. Cosmetic injections (filler and/or toxins, i.e. Juvederm, Radiesse, Botox, etc.), non-ablative laser or fractional laser resurfacing (time frame 12 months)
    5. Accutane® or other oral retinoid, Ablative procedures (i.e. laser, chemical) (time frame 12 months)
  • Individuals who have any planned surgeries or procedures during the study.
  • Individuals who participated in a facial usage study within the last 30 days, or who are currently participating on another usage study.
  • Individuals currently on or planning to participate on any type of research study at another facility or a doctor's office during this study.
Sex/Gender
Sexes Eligible for Study: Female
Ages 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts
Contact: Clinical Trials Registry Team 877-277-8566 IR-CTRegistration@Allergan.com
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT03767400
Other Study ID Numbers SCRIC18-OCT-01
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party Allergan
Study Sponsor Allergan
Collaborators Not Provided
Investigators
Principal Investigator: Lisa Goberdhan Allergan
PRS Account Allergan
Verification Date April 2019